English, PDF, 306kb
Excellent population health status and good outcomes associated with acute care reflect a high-performing health system in Norway. Norway’s good health system comes at a cost – Norway’s per capita health expenditure is the highest in Europe.
L’amélioration du dispositif de soins primaires et de la coordination des services de santé aiderait la Norvège à répondre à l’évolution des besoins de son système de santé, compte tenu du vieillissement de la population et du raccourcissement des séjours à l’hôpital, selon un nouveau rapport de l’OCDE.
La Norvège est mieux armée que la plupart des autres pays pour faire face au vieillissement de la population.
Tackling mental ill-health of the working-age population is becoming a key issue for labour market and social policies in OECD countries. OECD governments increasingly recognise that policy has a major role to play in keeping people with mental ill-health in employment or bringing those outside of the labour market back to it, and in preventing mental illness. This report on Norway is the fourth in a series of reports looking at
To assess the feasibility of using secondary data sets information to feed an output-based PPP approach for hospital services, we reviewed the main characteristics of diagnoses and procedures coding standards, DRG classification systems, and cost-finding methods used in selected OECD countries.
The mortality amenable to health care is defined as a possible indicator to measure the health care systems performance in preventing premature deaths that can be avoided by appropriate health care intervention. This paper assesses the feasibility of using this indicator in OECD countries.
Summarises proceedings of a conference looking at examples of human genetic research databases, how they are established, how they are managed and governed, how they might be commercialised, and what the policy considerations might be.
This publication examines the innovation system in pharmaceutical biotechnology in eight OECD countries. Based on rich evidence, it draws policy recommendations to foster innovation in biopharmaceuticals advocating an integrated policy approach.